Pfizer Collaborates with Arvinas for Breast Cancer Therapy

By Shikha Kashyap

Pharma Deals Review: Vol 2021 Issue 8 (Table of Contents)

Published: 20 Aug-2021

DOI: 10.3833/pdr.v2021.i8.2634     ISSN: 1756-7874

Section: Research & Development



Strengthening its commitment to oncology, Pfizer has entered into a collaboration with Arvinas to develop and commercialise an investigational oral proteolysis targeting chimera (PROTAC) oestrogen receptor protein degrader, ARV-471, for the treatment of breast cancer...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details